Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0R9ZB
|
|||
| Former ID |
DAP000327
|
|||
| Drug Name |
Propiomazine
|
|||
| Synonyms |
Phenoctyl; Propiomazina; Propiomazinum; Propionylpromethazine; Dorevan (TN); Dorevane (TN); Indorm (TN); Largon (TN); Propavan (TN); Propiomazina [INN-Spanish]; Propiomazinum [INN-Latin]; Serentin (TN); Wy-1359; Propiomazine (USAN/INN); Propiomazine [USAN:BAN:INN]; Propiomazine [USAN:INN:BAN]; 1-(10-(2-(Dimethylamino)propyl)phenothiazin-2-yl)-1-propanone; 1-[10-[2-(dimethylamino)propyl]phenothiazin-2-yl]propan-1-one; 1-{10-[2-(dimethylamino)propyl]-10H-phenothiazin-2-yl}propan-1-one; 10-(2-Dimethylaminopropyl)-2-propionylphenothiazine; 10-Dimethylaminoisopropyl-2-propionylphenothiazine; 2-Propionyl-10-(2-(dimethylamino)propyl)phenothiazine; 3-Propionyl-10-dimethylaminoisopropylphenothiazine
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Insomnia [ICD-11: 7A00-7A0Z] | Approved | [1], [2], [3] | |
| Therapeutic Class |
Sedatives and Hypnotics
|
|||
| Company |
Hikma Maple Ltd
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C20H24N2OS
|
|||
| Canonical SMILES |
CCC(=O)C1=CC2=C(C=C1)SC3=CC=CC=C3N2CC(C)N(C)C
|
|||
| InChI |
1S/C20H24N2OS/c1-5-18(23)15-10-11-20-17(12-15)22(13-14(2)21(3)4)16-8-6-7-9-19(16)24-20/h6-12,14H,5,13H2,1-4H3
|
|||
| InChIKey |
UVOIBTBFPOZKGP-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 362-29-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
9609, 5371491, 7849420, 7980415, 8153047, 10520217, 11335471, 11360710, 11363766, 11366328, 11368890, 11371837, 11374140, 11377052, 11461682, 11484576, 11488746, 11490375, 11492306, 11494686, 14802382, 29224018, 46506205, 47216685, 47736372, 47959643, 48334386, 48416479, 50023903, 50123416, 50721675, 56352892, 57322540, 85209519, 85789212, 104307837, 124955689, 125823477, 129426836, 134337639, 134973797, 137009964, 140649124, 160964120, 162185625, 178103858, 179038464, 226471484, 241060511, 249935360
|
|||
| ChEBI ID |
CHEBI:8491
|
|||
| SuperDrug ATC ID |
N05CM06
|
|||
| SuperDrug CAS ID |
cas=000362298
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Histamine H1 receptor (H1R) | Target Info | Antagonist | [4] |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Inflammatory mediator regulation of TRP channels | ||||
| Panther Pathway | Histamine H1 receptor mediated signaling pathway | |||
| Reactome | Histamine receptors | |||
| G alpha (q) signalling events | ||||
| WikiPathways | Monoamine GPCRs | |||
| GPCRs, Class A Rhodopsin-like | ||||
| IL-4 Signaling Pathway | ||||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7284). | |||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 012382. | |||
| REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | |||
| REF 4 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.